天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Toggle Nav
Close
  • Menu
  • Setting

Bedaquiline

Catalog No.
B3492
anti-tuberculosis drug
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$77.00
In stock
5mg
$61.00
In stock
10mg
$83.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Bedaquiline is a diarylquinoline drug and inhibits Mycobacterium tuberculosis F1FO-ATP synthase by simultaneously targeting the subunit c and subunit ε. Bedaquiline has uncoupling activity and is used for the multi-drug resistant tuberculosis[1].?

Bedaquiline has anticancer activity against cancer stem cell-like cells. Bedaquiline treatment of MCF7 breast cancer cells can inhibit mitochondrial oxygen consumption and glycolysis, but can induce oxidative stress. Bedaquiline can reduce mitochondrial membrane potential and significantly increase ROS levels[2].?

Bedaquiline follows the principle of three-stage elimination, and its terminal half-life is very long, approximately 173 hours in humans[3].?

References:

[1]. Jang J C, Jung Y G, Choi J, et al. Bedaquiline susceptibility test for totally drug-resistant tuberculosisMycobacterium tuberculosis. Journal of Microbiology, 2017, 55(6): 483-487.

[2]. Fiorillo M, Lamb R, Tanowitz H, et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging, 2016, 8(8): 1593-1607.

[3]. Lakshmanan M, Xavier A S. Bedaquiline–The first ATP synthase inhibitor against multi drug resistant tuberculosis. Journal of Young Pharmacists, 2013, 5(4): 112-115.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt525.5
Cas No.843663-66-1
FormulaC31H29BrN2O
Solubility≥22.05 mg/mL in DMSO with gentle warming; insoluble in EtOH; insoluble in H2O
Chemical Name(1R,2S)-1-(6-bromoquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol
SDFDownload SDF
Canonical SMILESCN(C)CC[C@@]([C@H](C1=CC=CC=C1)C2=CC3=CC(Br)=CC=C3N=C2)(O)C4=CC=CC5=C4C=CC=C5
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

MCF-7 human breast cancer cells

Reaction Conditions

48 h incubation

Applications

Bedaquiline treatment (10 μM) of MCF-7 breast cancer cells inhibited mitochondrial oxygen-consumption, as well as glycolysis, but induced oxidative stress. Importantly, bedaquiline significantly blocked the propagation and expansion of MCF-7-derived cancer stem cells, with an IC50 value of ~ 1 μM.

Animal experiment:[2]

Animal models

Mice infected with Mycobacterium tuberculosis (M. tuberculosis)

Dosage form

25 mg/kg

Administered orally, 5 days per week, for 14 weeks

Applications

The bedaquiline-containing regimen (rifampicin, isoniazid, pyrazinamide and bedaquiline) achieved total organ cfu count clearance at 8 weeks after treatment initiation, faster than the standard regimen consisting of rifampicin, isoniazid, pyrazinamide and ethambutol (14 weeks). Furthermore, the bedaquiline-containing regimen removed culture filtrate-dependent persistent bacilli at 8 weeks, leading to no disease relapse.

Note

The technical data provided above is for reference only.

References:

1. Fiorillo M, Lamb R, Tanowitz HB, et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (Albany NY), 2016, 8(8): 1593-1607.

2. Hu Y, Pertinez H, Liu Y, et al. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure. Journal of Antimicrobial Chemotherapy, 2019, 74(6): 1627-1633.

Quality Control